Deconstructing nucleotide binding activity of the Mdm2 RING domain

Nucleic Acids Research

Volumn 38, Issue 21, 2010, Pages 7587-7598

  Priest, Christina ^a   Prives, Carol ^a   Poyurovsky, Masha V ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN MDM2; PROTEIN MDMX;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE DELETION; GENE MAPPING; GENETIC CONSERVATION; NUCLEOTIDE BINDING SITE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

ADENINE; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BINDING SITES; HUMANS; MAGNESIUM; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 78649828256     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkq669     Document Type: Article

References (54)

1. Vousden, K. H. and Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413-431.
2. Kruse, J. P. and Gu, W. (2009) Modes of p53 regulation. Cell, 137, 609-622.
3. Wade, M., Wang, Y. V. and Wahl, G. M. (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol., 20, 299-309.
4. Marine, J. C. and Lozano, G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ., 17, 93-102.
5. Leng, P., Brown, D. R., Shivakumar, C. V., Deb, S. and Deb, S. P. (1995) N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene, 10, 1275-1282.
6. Chen, J., Marechal, V. and Levine, A. J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol., 13, 4107-4114.
7. Meulmeester, E., Frenk, R., Stad, R., de Graaf, P., Marine, J. C., Vousden, K. H. and Jochemsen, A. G. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol., 23, 4929-4938.
8. Kawai, H., Wiederschain, D., Kitao, H., Stuart, J., Tsai, K. K. and Yuan, Z. M. (2003) DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem., 278, 45946-45953.
9. Lindstrom, M. S., Jin, A., Deisenroth, C., White Wolf, G. and Zhang, Y. (2007) Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol., 27, 1056-1068.
10. Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J. and Wright, P. E. (2006) Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J. Mol. Biol., 363, 433-450.
11. Lai, Z., Freedman, D. A., Levine, A. J. and McLendon, G. L. (1998) Metal and RNA binding properties of the hdm2 RING finger domain. Biochemistry, 37, 17005-17015.
12. Sharp, D. A., Kratowicz, S. A., Sank, M. J. and George, D. L. (1999) Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem., 274, 38189-38196.
13. Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A. and Ohtsubo, M. (1999) MDM2 interacts with MDMX through their RING finger domains. FEBS Lett., 447, 5-9.
14. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
15. Brooks, C. L. and Gu, W. (2006) p53 ubiquitination: Mdm2 and beyond. Mol. Cell, 21, 307-315.
16. Wade, M. and Wahl, G. M. (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol. Cancer Res., 7, 1-11.
17. Marine, J. C., Dyer, M. A. and Jochemsen, A. G. (2007) MDMX: from bench to bedside. J. Cell. Sci., 120, 371-378.
18. Marine, J. C. and Jochemsen, A. G. (2005) Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun., 331, 750-760.
19. Kentsis, A., Gordon, R. E. and Borden, K. L. (2002) Control of biochemical reactions through supramolecular RING domain self-assembly. Proc. Natl Acad. Sci. USA, 99, 15404-15409.
20. Kentsis, A., Gordon, R. E. and Borden, K. L. (2002) Self-assembly properties of a model RING domain. Proc. Natl Acad. Sci. USA, 99, 667-672.
21. Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z. Q., Pavletich, N. and Prives, C. (2007) The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J., 26, 90-101.
22. Uldrijan, S., Pannekoek, W. J. and Vousden, K. H. (2007) An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J., 26, 102-112.
23. Singh, R. K., Iyappan, S. and Scheffner, M. (2007) Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J. Biol. Chem., 282, 10901-10907.
24. Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G. and Yuan, Z. M. (2002) Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. J. Biol. Chem., 277, 19251-19254.
25. Okamoto, K., Taya, Y. and Nakagama, H. (2009) Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase. FEBS Lett., 583, 2710-2714.
26. Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D. and Yuan, Z. M. (2007) RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res., 67, 6026-6030.
27. Lohrum, M. A., Ashcroft, M., Kubbutat, M. H. and Vousden, K. H. (2000) Identification of a cryptic nucleolar-localization signal in MDM2. Nat. Cell. Biol., 2, 179-181.
28. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T. and Levine, A. J. (1996) The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med., 2, 439-451.
29. Wawrzynow, B., Pettersson, S., Zylicz, A., Bramham, J., Worrall, E., Hupp, T. R. and Ball, K. L. (2009) A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J. Biol. Chem., 284, 11517-11530.
30. Walker, J. E., Saraste, M., Runswick, M. J. and Gay, N. J. (1982) Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J., 1, 945-951.
31. Saraste, M., Sibbald, P. R. and Wittinghofer, A. (1990) The P-loop-a common motif in ATP- and GTP-binding proteins. Trends Biochem. Sci., 15, 430-434.
32. Poyurovsky, M. V., Jacq, X., Ma, C., Karni-Schmidt, O., Parker, P. J., Chalfie, M., Manley, J. L. and Prives, C. (2003) Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Mol. Cell, 12, 875-887.
33. Ashcroft, M., Taya, Y. and Vousden, K. H. (2000) Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol., 20, 3224-3233.
34. Wawrzynow, B., Zylicz, A., Wallace, M., Hupp, T. and Zylicz, M. (2007) MDM2 chaperones the p53 tumor suppressor. J. Biol. Chem., 282, 32603-32612.
35. Stevens, C., Pettersson, S., Wawrzynow, B., Wallace, M., Ball, K., Zylicz, A. and Hupp, T. R. (2008) ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1. FEBS J., 275, 4875-4886.
36. Frasch, W. D. (2000) The participation of metals in the mechanism of the F(1)-ATPase. Biochim. Biophys. Acta, 1458, 310-325.
37. Lavie, A. and Konrad, M. (2004) Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase. Mini. Rev. Med. Chem., 4, 351-359.
38. Witkowski, J. T., Robins, R. K., Khare, G. P. and Sidwell, R. W. (1973) Synthesis and antiviral activity of 1, 2, 4-triazole-3-thiocarboxamide and 1, 2, 4-triazole-3-carboxamidine ribonucleosides. J. Med. Chem., 16, 935-937.
39. Brown, G. B. and Weliky, V. S. (1953) The synthesis of 9-beta-D-ribofuranosylpurine and the identity of nebularine. J. Biol. Chem., 204, 1019-1024.
40. Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J. et al. (2004) Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 351, 438-450.
41. Bernstein, D. I., Reuman, P. D., Sherwood, J. R., Young, E. C. and Schiff, G. M. (1988) Ribavirin small-particle-aerosol treatment of influenza B virus infection. Antimicrob. Agents Chemother., 32, 761-764.
42. Chang, T. W. and Heel, R. C. (1981) Ribavirin and inosiplex: a review of their present status in viral diseases. Drugs, 22, 111-128.
43. Tseng, W. C., Derse, D., Cheng, Y. C., Brockman, R. W. and Bennett, L. L. Jr (1982) In vitro biological activity of 9-beta-D-arabinofuranosyl-2- fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol., 21, 474-477.
44. Robak, T., Korycka, A., Lech-Maranda, E. and Robak, P. (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules, 14, 1183-1226.
45. Huang, P., Chubb, S. and Plunkett, W. (1990) Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J. Biol. Chem., 265, 16617-16625.
46. Sack, J. S., Kish, K. F., Pokross, M., Xie, D., Duke, G. J., Tredup, J. A., Kiefer, S. E. and Newitt, J. A. (2008) Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase. Acta Crystallogr. D Biol. Crystallogr., D64, 705-710.
47. Zylberg, J., Ecke, D., Fischer, B. and Reiser, G. (2007) Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochem. J., 405, 277-286.
48. Garuti, L., Roberti, M. and Bottegoni, G. (2009) Small molecule aurora kinases inhibitors. Curr. Med. Chem., 16, 1949-1963.
49. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J. and McCredie, K. B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
50. Huang, P. and Plunkett, W. (1991) Action of 9-beta-D-arabinofuranosyl-2- fluoroadenine on RNA metabolism. Mol. Pharmacol., 39, 449-455.
51. 0-deoxyadenosine. Proc. Natl Acad. Sci. USA, 89, 2970-2974.
52. Deisenroth, C. and Zhang, Y. (2010) Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 1-8.
53. Zhang, Y. and Lu, H. (2009) Signaling to p53: ribosomal proteins find their way. Cancer Cell, 16, 369-377.
54. Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. and Lane, D. P. (2009) Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer, 9, 862-873.